Dynatrace, Inc. (NYSE:DT – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the twenty-three analysts that are currently covering the firm, Marketbeat reports. Six analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $59.70.
Several research analysts have issued reports on the company. Needham & Company LLC reissued a “hold” rating on shares of Dynatrace in a research report on Tuesday, August 6th. Wells Fargo & Company lowered their price objective on Dynatrace from $60.00 to $50.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Scotiabank lifted their price objective on Dynatrace from $52.00 to $55.00 and gave the company a “sector outperform” rating in a research report on Thursday, August 8th. Guggenheim lowered their price objective on Dynatrace from $60.00 to $55.00 and set a “buy” rating on the stock in a research report on Tuesday, July 16th. Finally, Piper Sandler assumed coverage on Dynatrace in a research report on Thursday, June 27th. They set a “neutral” rating and a $50.00 price objective on the stock.
Read Our Latest Analysis on Dynatrace
Insiders Place Their Bets
Hedge Funds Weigh In On Dynatrace
A number of large investors have recently bought and sold shares of DT. Eminence Capital LP purchased a new position in Dynatrace during the 2nd quarter valued at $158,369,000. Jericho Capital Asset Management L.P. purchased a new position in Dynatrace during the 1st quarter valued at $133,701,000. Norges Bank purchased a new position in Dynatrace during the 4th quarter valued at $148,515,000. Vanguard Group Inc. lifted its holdings in shares of Dynatrace by 9.8% in the 4th quarter. Vanguard Group Inc. now owns 26,264,280 shares of the company’s stock worth $1,436,393,000 after buying an additional 2,348,246 shares during the period. Finally, Assenagon Asset Management S.A. lifted its holdings in shares of Dynatrace by 1,146.0% in the 2nd quarter. Assenagon Asset Management S.A. now owns 2,208,137 shares of the company’s stock worth $98,792,000 after buying an additional 2,030,915 shares during the period. Hedge funds and other institutional investors own 94.28% of the company’s stock.
Dynatrace Stock Performance
Shares of NYSE:DT opened at $52.49 on Wednesday. The stock has a market capitalization of $15.65 billion, a price-to-earnings ratio of 100.94, a PEG ratio of 7.63 and a beta of 1.05. The stock’s 50-day simple moving average is $47.97 and its two-hundred day simple moving average is $46.61. Dynatrace has a 52-week low of $39.42 and a 52-week high of $61.41.
Dynatrace (NYSE:DT – Get Free Report) last announced its earnings results on Wednesday, August 7th. The company reported $0.33 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.29 by $0.04. The business had revenue of $399.20 million for the quarter, compared to analysts’ expectations of $392.22 million. Dynatrace had a return on equity of 9.77% and a net margin of 10.36%. The business’s revenue for the quarter was up 19.9% on a year-over-year basis. During the same period last year, the firm posted $0.16 earnings per share. As a group, equities analysts forecast that Dynatrace will post 0.71 earnings per share for the current fiscal year.
Dynatrace Company Profile
Dynatrace, Inc provides a security platform for multicloud environments. It operates Dynatrace, a security platform, which provides application and microservices monitoring, runtime application security, infrastructure monitoring, log management and analytics, digital experience monitoring, digital business analytics, and cloud automation.
Featured Stories
- Five stocks we like better than Dynatrace
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- How to Most Effectively Use the MarketBeat Earnings Screener
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- How to Effectively Use the MarketBeat Ratings Screener
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Dynatrace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynatrace and related companies with MarketBeat.com's FREE daily email newsletter.